Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03763149
Title A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Innovent Biologics (Suzhou) Co. Ltd.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.